94E Stock Overview
A clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Zura Bio Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.60 |
| 52 Week High | US$5.50 |
| 52 Week Low | US$1.73 |
| Beta | 0.14 |
| 11 Month Change | -37.50% |
| 3 Month Change | -26.55% |
| 1 Year Change | -33.33% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -69.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| 94E | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -12.8% | -0.2% | 0.8% |
| 1Y | -33.3% | -16.9% | 9.1% |
Return vs Industry: 94E underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 94E underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| 94E volatility | |
|---|---|
| 94E Average Weekly Movement | 11.6% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 94E's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 94E's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 15 | Rob Lisicki | zurabio.com |
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
Zura Bio Limited Fundamentals Summary
| 94E fundamental statistics | |
|---|---|
| Market cap | €169.84m |
| Earnings (TTM) | -€40.60m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.7x
P/E RatioIs 94E overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 94E income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$42.62m |
| Earnings | -US$42.62m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.65 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 94E perform over the long term?
See historical performance and comparison